Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunopheresis with LW-02 in Advanced Breast Cancer
NCT04004910Phase 2Unknown
- Sponsor
- Immunicom, Inc.
- Start
- May 2019
- Primary completion
- Dec 2022
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in breast cancer (3 arms), sponsored by Immunicom, Inc. Primary endpoints: Soluble Tumor Necrosis Factor Receptor (sTNFR) concentrations in plasma at 16 weeks, Safety and Tolerability Assessment at 16 weeks and 3 more. Status: unknown.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04004910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004910.